126 related articles for article (PubMed ID: 12466641)
1. Raising hemoglobin: an opportunity for increasing survival?
Thomas GM
Oncology; 2002; 63 Suppl 2():19-28. PubMed ID: 12466641
[TBL] [Abstract][Full Text] [Related]
2. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
[TBL] [Abstract][Full Text] [Related]
3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin and radiotherapy: a dangerous combination?
Dunst J
Strahlenther Onkol; 2004 Mar; 180(3):133-5. PubMed ID: 15032246
[No Abstract] [Full Text] [Related]
5. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment.
Harrison LB; Shasha D; Homel P
Oncology; 2002; 63 Suppl 2():11-8. PubMed ID: 12466640
[TBL] [Abstract][Full Text] [Related]
7. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
[TBL] [Abstract][Full Text] [Related]
8. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
9. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
10. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
11. Anemia correction in malignancy management: threat or opportunity?
De Los Santos JF; Thomas GM
Gynecol Oncol; 2007 May; 105(2):517-29. PubMed ID: 17367848
[TBL] [Abstract][Full Text] [Related]
12. The impact of hemoglobin levels on treatment outcomes in patients with cancer.
Littlewood TJ
Semin Oncol; 2001 Apr; 28(2 Suppl 8):49-53. PubMed ID: 11395853
[TBL] [Abstract][Full Text] [Related]
13. Anemia in cancer patients: significance, epidemiology, and current therapy.
Tchekmedyian NS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
[TBL] [Abstract][Full Text] [Related]
14. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
16. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?
Harrison L; Blackwell K
Oncologist; 2004; 9 Suppl 5():31-40. PubMed ID: 15591420
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
